Edgewise Therapeutics, Inc.
General ticker "EWTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.4B (TTM average)
Edgewise Therapeutics, Inc. follows the US Stock Market performance with the rate: 53.4%.
Estimated limits based on current volatility of 2.8%: low 40.99$, high 43.37$
Factors to consider:
- Total employees count: 146 (+32.7%) as of 2025
- Top business risk factors: No approved products, Clinical trial delays, Regulatory and compliance, Manufacturing risks, Capital shortage
- Current price 46.7% above estimated high
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [13.36$, 28.62$]
- 2026-12-31 to 2027-12-31 estimated range: [10.81$, 24.23$]
Financial Metrics affecting the EWTX estimates:
- Negative: with PPE of -14.9 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -5.74 <= 0.28
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 94.51 > 63.63
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term EWTX quotes
Long-term EWTX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $114.36MM | $158.83MM | $191.41MM |
| Operating Income | $-114.36MM | $-158.83MM | $-191.41MM |
| Non-Operating Income | $14.19MM | $25.02MM | $23.61MM |
| R&D Expense | $90.91MM | $126.97MM | $151.39MM |
| Income(Loss) | $-100.16MM | $-133.81MM | $-167.79MM |
| Net Income(Loss)* | $-100.16MM | $-133.81MM | $-167.79MM |
| Stockholders Equity | $318.83MM | $459.22MM | $522.26MM |
| Assets | $340.04MM | $486.82MM | $552.60MM |
| Operating Cash Flow | $-91.95MM | $-109.03MM | $-143.82MM |
| Capital expenditure | $5.75MM | $1.31MM | $0.26MM |
| Investing Cash Flow | $102.89MM | $-184.66MM | $-32.79MM |
| Financing Cash Flow | $53.17MM | $249.25MM | $196.09MM |
| Earnings Per Share** | $-1.57 | $-1.45 | $-1.63 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.